Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Allergy Immunotherapy Market size was over USD 2.9 billion in 2024 and is estimated to reach USD 9.3 billion by the end of 2037, exhibiting a CAGR of 10.1% during the forecast period, i.e., 2025-2037. In 2025, the industry size of allergy immunotherapy is evaluated at USD 3.3 billion.
The allergy immunotherapy market is characterized by the increasing burden of allergic conditions across the world. As per the Centers for Disease Control and Prevention, about 8% of population in the U.S. population is reported to be diagnosed with allergic rhinitis, mainly due to environmental and genetic predispositions. Additionally, the rising instances of allergies associated with the respiratory tract, that is, 400 million cases, due to pollution and weather changes, are also fueling growth in the sector. This further creates a heightened awareness among both healthcare professionals and patients, intensifying the therapeutic demand.
Furthermore, the supply chain for the products in allergy immunotherapy comprises raw material sourcing, active pharmaceutical ingredients, biologic manufacturing, and medical device development, such as injection devices for subcutaneous immunotherapy. These APIs and vaccines are imported from regions with substantial manufacturing capabilities. In this context, import-export activities from the U.S. Department of Commerce demonstrated a lucrative increase in import activities that as U.S. imports of pharmaceuticals increased by 12% between 2020 and 2023.
Allergic Immunotherapy Sector: Growth Drivers and Challenges
Growth Drivers
- Government funding activities: One of the major factors driving growth in the allergy immunotherapy market is the increasing funding from government and public healthcare initiatives. According to a report from Medicare, the medical expenditure for allergy-associated therapies reached nearly USD 4.2 billion in 2023, with considerable amounts particularly granted for immunotherapy products to improve patient outcomes. Additionally, the regulatory frameworks, such as the U.S. FDA, support with appropriate approvals in supporting development of innovative immunotherapy products, enabling greater affordability for treatments.
- Advancements in personalized medicine: Another major factor driving growth in the market is the innovative and personalized therapeutic measures. This ability to customize the management relying on the patient's medical profile has created immense awareness due to its higher efficacy and low side effects. As per a 2023 National Institutes of Health report, people who received personalized allergy immunotherapy demonstrated a 30% higher effectiveness compared to traditional methods. This global shift toward stratified is expected to improve patient outcomes, further boosting market demand.
Revenue Potential for Allergy Immunotherapy Manufacturers
The key strategies adopted by global manufacturers leveraging allergy immunotherapy products are product innovations, collaborations, and market expansions to expand their revenue potential. With increased focus on personalized medicine and treatment accessibility, the firm gained substantial revenue growth. For instance, in 2023, Stallergenes Greer expanded its market share by 21.7% with the initiation of next-generation immunotherapy products for patients with multi-sensitivities, which resulted in additional USD 255.4 million in revenue. Hence, such expansion strategies coupled with government healthcare initiatives, are inspiring the key players to launch more of such effective and affordable treatments.
Revenue Potential Analysis
|
Company |
Market Share Increase (%) |
Additional Revenue (USD Million) |
|
Stallergenes Greer |
21.7% |
255.4 |
|
ALK-Abelló |
15.4% |
180.7 |
|
Allergopharma |
12.6% |
120.2 |
Feasibility Models for Allergy Immunotherapy Market Expansion
The demand for allergy immunotherapy is in a surge, which has inspired manufacturers to adopt various sorts of feasible expansion models, such as partnerships with domestic healthcare providers and confining the product to enhance market penetration. In this regard, India experienced a 12.3% revenue increase that is from 2022 to 2024, as the allergy immunotherapy suppliers have partnered with domestic healthcare professionals, aiming to offer affordable therapeutic measures. Hence, these expansion models are crucial in shaping business growth, especially in emerging markets, ensuring that these solutions reach a wider consumer base.
Revenue Feasibility Models for Allergy Immunotherapy Expansion
|
Region |
Expansion Model |
Revenue Increase (%) |
|
India |
Partnership with local healthcare providers |
12.3% |
|
China |
Localized product offerings with regional distributors |
14.7% |
|
Brazil |
Government healthcare program collaboration |
10.4% |
|
South Africa |
Market expansion through public-private partnerships |
17.8% |
Challenges
- Uneven market access: One of the major challenges posed by the market is the uneven market access, particularly in the emerging regions. This is mainly influenced by expensive therapeutic costs associated with allergic immunotherapy and a lack of public awareness, which makes it difficult for the products to reach the targeted group of patients. Additionally, the products from allergy immunotherapy are often unavailable in the rural areas of developing regions due to their high costs and low insurance subsidies, thereby hindering market upliftment.
- Stringent regulatory hurdles: Another significant challenge posed by the market is the strict regulatory approvals from the governing bodies. These processes often involve rigorous preclinical testing, clinical trials, resulting in delayed market entry of the new product. These delays, in turn, increase development costs for manufacturers and slow down patient access to innovative treatments. Thus, this acts as a major hurdle to creating health disparities in the communities.
Allergy Immunotherapy Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
10.1% |
|
Base Year Market Size (2024) |
USD 2.9 billion |
|
Forecast Year Market Size (2037) |
USD 9.3 billion |
|
Regional Scope |
|
Allergy Immunotherapy Segmentation
Allergy Type (Allergic Rhinitis, Allergic Asthma, Conjunctivitis)
Based on the allergy type, the allergic rhinitis segment is projected to account for a lucrative share of 60.4% in the allergy immunotherapy market during the forecast period. The dominance of the segment is attributable to the rising occurrence of allergic rhinitis across the world, which significantly contributes to the market expansion. Additionally, the push for both subcutaneous immunotherapy, sublingual immunotherapy in rhinitis treatment is inspiring the global pharma leaders to invest in such therapeutic measures, driving the adoption of immunotherapy for rhinitis.
Treatment Type (Subcutaneous Immunotherapy, Sublingual Immunotherapy)
Based on treatment type, the subcutaneous immunotherapy segment is expected to garner the highest share of 52.4% in the allergy immunotherapy market by the end of 2037. The dominance of the segment is attributable to its capability to offer reliable solutions for severe allergies and develop resistance against allergens. The subcutaneous immunotherapy demonstrated exceptional positive outcomes in treating conditions such as allergic rhinitis, asthma, and other allergic conditions. This is the evidence for a wider scope fueled by increasing healthcare access, well-established conventions, and proven efficacy of this element as a reliable solution.
Our in-depth analysis of the global market includes the following segments:
|
Allergy Type |
|
|
Treatment Type |
|
|
Distribution Channel |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportAllergy Immunotherapy Industry - Regional Synopsis
North America Market Analysis
The North America allergy immunotherapy market is anticipated to account for more than 51.5% of the global market share by the end of 2037. The dominance of the region is attributable to a large patient pool and strong support from the country’s government, which is with their funding initiatives. Additionally, the increased awareness about the allergic conditions of immunotherapy and the advancements in sublingual immunotherapy are significantly contributing to the market growth in the region. Furthermore, the growing adoption of personalized medicine and favourable reimbursement policies are shaping market expansion.
The allergic immunotherapy market in the U.S. is gaining traction, with exceptional government support and private sector investments in the medical industry. For instance, as stated by Medicare, the healthcare spending associated with allergen treatments increased by 15% from 2020 to 2024, which highlights the increased medical access to patients in the country. In addition, the federal government granted a budget of USD 5 billion in 2023 from both Medicare and Medicaid for allergy treatments in the country. Hence, such factors are expected to support the market progression during the forecast period with enhanced treatment access.
The Canada allergy immunotherapy market is projected to grow steadily, with government-backed funding and notable healthcare investments. For instance, in 2023, Canada administered a total of 8% of its healthcare budget towards allergy treatments, which is approximately 3.1 billion, to widen the treatment access in the country. Furthermore, the healthcare initiatives in Ontario and British Columbia witnessed an 18% increase in funding from 2021 to 2024, which is reported to benefit 200,000 patients annually. Thus, the country's market is anticipated to grow at a considerable rate with such initiatives.
APAC Market Analysis
The Asia-Pacific allergy immunotherapy market is experiencing significant growth, driven by increasing prevalence of allergic diseases, rising healthcare expenditure, and government-associated initiatives in countries such as Japan, China, India, South Korea, and Malaysia. Additionally, the rapid urbanization is creating a large patient pool owing to the increased pollution, which creates a heightened awareness of healthcare access in the region. The region’s market is projected to grow at a CAGR of 8.2% from 2025 to 2037, with support from governments to drive further growth.
China is a global leader in the market, which is exceptionally supported by increasing instances of allergic diseases in the country. The National Medical Products Administration reported that the government expenditure rose by 15% over the previous 5 years, which estimated the number of patients affected with allergies to be 1.6 billion in 2023. Furthermore, as the population exceeds 1.5 billion, the demand for management strategies also expands rapidly. Those factors strengthen the domestic production of allergy immunotherapy products in the country, positioning China as a key leader in the Asia Pacific.
India is steadily consolidating its position in the market with the rising demand for affordable management therapies. The country is also accumulating government funding to leverage immunotherapy that Between 2015 to 2023, the expenditure rose by 18%, which is 1.7 billion annually. It is further reported that approximately 2.5 million people received allergy treatments in 2023. The country also accounted for increased instances of rhinitis and asthma, fueling the sector to expand more and support the broader availability of allergy immunotherapy.
Companies Dominating the Allergy Immunotherapy Landscape
-
The competitive landscape of the allergy immunotherapy market is inspiring the global players to expand their market share. Companies involved in the emerging markets of the U.S., such as Thermo Fisher Scientific and Regeneron Pharmaceuticals, are leveraging advanced injectable treatments. While other key players, including ALK-Abelló and Stallergenes Greer, are dominating the industry with sublingual and subcutaneous treatments. This is further dragging the interest in conducting research activities and bringing innovation in the field, especially for biologics and immunotherapies targeting severe allergic reactions.
Company Name
Country of Origin
Industry Focus
ALK-Abelló A/S
Denmark
SLIT/SCIT therapies for pollen, mite, and food allergies
Stallergenes Greer
Switzerland
Global SLIT and SCIT manufacturer, broad allergen portfolio
Allergy Therapeutics
UK
SCIT and peptide-based immunotherapy
HAL Allergy B.V.
Netherlands
SCIT/SLIT for airborne allergens and insect venoms
DBV Technologies
France
Epicutaneous immunotherapy (EPIT) focuses on food allergy
Jubilant HollisterStier
USA/India
Contract manufacturing of allergy immunotherapy products
Circassia Group
UK
Biopharmaceuticals with an allergy focus (divested in recent years)
Zydus Lifesciences
India
Allergy vaccines and biologics, expanding the immunotherapy line
Biogenics Research & Training
India
Focused on allergy vaccine development and testing
Inmunotek S.L.
Spain
Manufacturer of allergen vaccines and diagnostics
BioPharma Laboratories
Australia
Allergy testing and immunotherapy production
Curalogic A/S (defunct)
Denmark
Developed allergy vaccines (merged/divested)
Alletess Medical Laboratory
USA
Allergy testing and personalized immunotherapy services
Medinova Laboratories
Malaysia
Local manufacturer of allergy treatment solutions
Hanmi Pharmaceutical
South Korea
R&D focuses on biologics, including allergy-related therapeutics
Protherics (BTG plc)
UK
Allergy and venom immunotherapy (now part of BTG)
Immunomic Therapeutics
USA
DNA-based immunotherapy platforms for allergies
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
Below are the areas covered for each company under the top 15 global manufacturers:
In the News
- In July 2024, Bencard Allergie GmbH launched sublingual immunotherapy tablets for dust mite and birch pollen allergies, aiming to reach growing patient demand in both Europe and North America.
- In 2024, Thermo Fisher Scientific unveiled an AI-powered diagnostic platform to accelerate allergy testing, making it more accurate and reducing testing times by 50%.
Author Credits: Radhika Pawar
- Report ID: 3769
- Published Date: May 12, 2025
- Report Format: PDF, PPT
